Overview

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Phase:

Phase 3

Details

Lead Sponsor:

Suven Life Sciences Limited

Treatments:

1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate